Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Oxford
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00461630CT.gov Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral Arterial Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Laropiprant (this asset) | University of Oxford | P3 | B · 61 |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BBB |
| Aspirin | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BBB |
| Cilostazol | University of Ioannina | P4 | BB |
| Ranolazine | Colorado Prevention Center | P4 | BB |
| Ticagrelor | AstraZeneca | P3 | BB |
| Ezetimibe | University of Oxford | P3 | B |
| Simvastatin | University of Oxford | P3 | B |
| Colchicinum | Population Health Research Institute | P3 | B |
+6 more in the Peripheral Arterial Disease cohort
Other indications for Laropiprant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hyperlipoproteinemia | — | P4 | B · 63 |
| Coronary Artery Disorder | — | P3 | B · 62 |
| Cardiovascular Disorder | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Laropiprant in Peripheral Arterial Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/laropiprant-peripheral-arterial-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →